<code id='88141CBE9F'></code><style id='88141CBE9F'></style>
    • <acronym id='88141CBE9F'></acronym>
      <center id='88141CBE9F'><center id='88141CBE9F'><tfoot id='88141CBE9F'></tfoot></center><abbr id='88141CBE9F'><dir id='88141CBE9F'><tfoot id='88141CBE9F'></tfoot><noframes id='88141CBE9F'>

    • <optgroup id='88141CBE9F'><strike id='88141CBE9F'><sup id='88141CBE9F'></sup></strike><code id='88141CBE9F'></code></optgroup>
        1. <b id='88141CBE9F'><label id='88141CBE9F'><select id='88141CBE9F'><dt id='88141CBE9F'><span id='88141CBE9F'></span></dt></select></label></b><u id='88141CBE9F'></u>
          <i id='88141CBE9F'><strike id='88141CBE9F'><tt id='88141CBE9F'><pre id='88141CBE9F'></pre></tt></strike></i>

          leisure time

          leisure time

          author:focus    Page View:6
          AI skin cancer detector, dermasensor. -- health tech coverage from STAT
          Around 5 million skin cancers are diagnosed each year in the United States. Skin cancer is common, but it’s also not that deadly when caught early. Courtesy DermaSensor

          The Food and Drug Administration cleared an AI-powered device for detecting skin cancer on Wednesday, giving primary care physicians a new way to evaluate troubling skin spots.

          Around 5 million skin cancers are diagnosed each year in the United States. Skin cancer is common, but most types are not that deadly when caught early.

          advertisement

          The device, developed by a small company called DermaSensor, is handheld and uses light to examine suspicious moles on a cellular level. It will be marketed specifically for primary care physicians to use in routine check-ups in patients aged 40 and above.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          A new approach to psychiatric drug development
          A new approach to psychiatric drug development

          AdobeInmanyways,psychiatryisstillflyingblind.Peopleexperiencingmentalhealthconditionsareprescribedva

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo